Curiox reports lower operator- and site-dependent variability with automated antibody cocktailing at ICCS 2026

Curiox has published a poster landing page for ICCS 2026 evaluating its Pluto Antibody Cocktailing Wizard across 9-, 10- and 24-colour panels. The company reports that five of six markers were at or below 5% CV, hands-on time fell from 6:26 manually to 3:18–4:34 with automation, cross-site vial-to-vial CV was 0.4% automated versus 1.9% manual, and concordance was r=0.997.

CFCM explainer — what is being tested

Manual antibody cocktail preparation → operator/site variability → automated cocktailing with Pluto ACW → reported reduction in preparation variability.

Source/credit: CFCM explainer based on Curiox's ICCS 2026 poster landing page. These are manufacturer-generated poster data, not independently reviewed clinical-performance evidence.

The numerical results are published by the manufacturer and need review of the complete poster methods, replicate structure, statistical analysis, instrument/reagent controls and clinical relevance before CFCM treats them as robust comparative evidence. The annual meeting runs 4–6 October, so the data are online before the scheduled meeting presentation. Reduced cocktail-preparation variability does not itself establish improved patient-level diagnostic accuracy or full end-to-end assay reproducibility.

Antibody master-mix preparation is an under-discussed source of pre-analytical variability in high-parameter flow. Curiox's poster provides quantitative evidence that automated cocktailing can reduce preparation variability and hands-on time in the tested workflows. CFCM publishes this as WATCH: the reported numbers are useful, but they do not by themselves establish patient-level diagnostic benefit or end-to-end assay equivalence.